Pathology of prostate cancer and focal therapy ('male lumpectomy')

Roberta Mazzucchelli, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Andrea B. Galosi, Ziya Kirkali, Rodolfo Montironi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Focal therapy of the prostate is defined as prostate gland ablation aiming at eradication of unifocal low-risk prostate cancer, and preserving uninvolved (peri-) prostatic tissue and therefore quality of life. The major arguments against focal therapy can be classified under the headings of understaging and multifocality. The argument of understaging highlights the importance of the occasional, but troublesome, finding of a large, extraprostatic or high-grade tumor (Gleason score ≥7) in about a quarter of radical prostatectomy specimens removed from men initially classified as having a low-risk tumor. Indeed, 85% of all prostate cancer cases are multifocal. These concerns can be offset by additional testing: another biopsy, especially a transperineal mapping biopsy, and magnetic resonance imaging (MRI) of the prostate. The technology needed to ablate small regions or sectors of the prostate harboring a known cancer is rapidly becoming available. Cryotherapy is already being used and the preliminary data are encouraging, Ultrasound-guided high-intensity focused ultrasound (HIFU), photodynamic therapy using newly developed light-sensitizing agents, and MRI-guided HIFU are all promising new tools.

Original languageEnglish
Pages (from-to)5155-5161
Number of pages7
JournalAnticancer Research
Volume29
Issue number12
StatePublished - Dec 2009

Fingerprint

Segmental Mastectomy
Prostate
Prostatic Neoplasms
Pathology
Magnetic Resonance Imaging
Biopsy
Neoplasms
Cryotherapy
Neoplasm Grading
Photochemotherapy
Therapeutics
Prostatectomy
Quality of Life
Technology
Light

Keywords

  • Focal therapy
  • Male lumpectomy
  • Prostate cancer
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mazzucchelli, R., Scarpelli, M., Cheng, L., Lopez-Beltran, A., Galosi, A. B., Kirkali, Z., & Montironi, R. (2009). Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Research, 29(12), 5155-5161.

Pathology of prostate cancer and focal therapy ('male lumpectomy'). / Mazzucchelli, Roberta; Scarpelli, Marina; Cheng, Liang; Lopez-Beltran, Antonio; Galosi, Andrea B.; Kirkali, Ziya; Montironi, Rodolfo.

In: Anticancer Research, Vol. 29, No. 12, 12.2009, p. 5155-5161.

Research output: Contribution to journalArticle

Mazzucchelli, R, Scarpelli, M, Cheng, L, Lopez-Beltran, A, Galosi, AB, Kirkali, Z & Montironi, R 2009, 'Pathology of prostate cancer and focal therapy ('male lumpectomy')', Anticancer Research, vol. 29, no. 12, pp. 5155-5161.
Mazzucchelli R, Scarpelli M, Cheng L, Lopez-Beltran A, Galosi AB, Kirkali Z et al. Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Research. 2009 Dec;29(12):5155-5161.
Mazzucchelli, Roberta ; Scarpelli, Marina ; Cheng, Liang ; Lopez-Beltran, Antonio ; Galosi, Andrea B. ; Kirkali, Ziya ; Montironi, Rodolfo. / Pathology of prostate cancer and focal therapy ('male lumpectomy'). In: Anticancer Research. 2009 ; Vol. 29, No. 12. pp. 5155-5161.
@article{ec0885b8c3a948eda208b3de46a104ea,
title = "Pathology of prostate cancer and focal therapy ('male lumpectomy')",
abstract = "Focal therapy of the prostate is defined as prostate gland ablation aiming at eradication of unifocal low-risk prostate cancer, and preserving uninvolved (peri-) prostatic tissue and therefore quality of life. The major arguments against focal therapy can be classified under the headings of understaging and multifocality. The argument of understaging highlights the importance of the occasional, but troublesome, finding of a large, extraprostatic or high-grade tumor (Gleason score ≥7) in about a quarter of radical prostatectomy specimens removed from men initially classified as having a low-risk tumor. Indeed, 85{\%} of all prostate cancer cases are multifocal. These concerns can be offset by additional testing: another biopsy, especially a transperineal mapping biopsy, and magnetic resonance imaging (MRI) of the prostate. The technology needed to ablate small regions or sectors of the prostate harboring a known cancer is rapidly becoming available. Cryotherapy is already being used and the preliminary data are encouraging, Ultrasound-guided high-intensity focused ultrasound (HIFU), photodynamic therapy using newly developed light-sensitizing agents, and MRI-guided HIFU are all promising new tools.",
keywords = "Focal therapy, Male lumpectomy, Prostate cancer, Review",
author = "Roberta Mazzucchelli and Marina Scarpelli and Liang Cheng and Antonio Lopez-Beltran and Galosi, {Andrea B.} and Ziya Kirkali and Rodolfo Montironi",
year = "2009",
month = "12",
language = "English",
volume = "29",
pages = "5155--5161",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Pathology of prostate cancer and focal therapy ('male lumpectomy')

AU - Mazzucchelli, Roberta

AU - Scarpelli, Marina

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Galosi, Andrea B.

AU - Kirkali, Ziya

AU - Montironi, Rodolfo

PY - 2009/12

Y1 - 2009/12

N2 - Focal therapy of the prostate is defined as prostate gland ablation aiming at eradication of unifocal low-risk prostate cancer, and preserving uninvolved (peri-) prostatic tissue and therefore quality of life. The major arguments against focal therapy can be classified under the headings of understaging and multifocality. The argument of understaging highlights the importance of the occasional, but troublesome, finding of a large, extraprostatic or high-grade tumor (Gleason score ≥7) in about a quarter of radical prostatectomy specimens removed from men initially classified as having a low-risk tumor. Indeed, 85% of all prostate cancer cases are multifocal. These concerns can be offset by additional testing: another biopsy, especially a transperineal mapping biopsy, and magnetic resonance imaging (MRI) of the prostate. The technology needed to ablate small regions or sectors of the prostate harboring a known cancer is rapidly becoming available. Cryotherapy is already being used and the preliminary data are encouraging, Ultrasound-guided high-intensity focused ultrasound (HIFU), photodynamic therapy using newly developed light-sensitizing agents, and MRI-guided HIFU are all promising new tools.

AB - Focal therapy of the prostate is defined as prostate gland ablation aiming at eradication of unifocal low-risk prostate cancer, and preserving uninvolved (peri-) prostatic tissue and therefore quality of life. The major arguments against focal therapy can be classified under the headings of understaging and multifocality. The argument of understaging highlights the importance of the occasional, but troublesome, finding of a large, extraprostatic or high-grade tumor (Gleason score ≥7) in about a quarter of radical prostatectomy specimens removed from men initially classified as having a low-risk tumor. Indeed, 85% of all prostate cancer cases are multifocal. These concerns can be offset by additional testing: another biopsy, especially a transperineal mapping biopsy, and magnetic resonance imaging (MRI) of the prostate. The technology needed to ablate small regions or sectors of the prostate harboring a known cancer is rapidly becoming available. Cryotherapy is already being used and the preliminary data are encouraging, Ultrasound-guided high-intensity focused ultrasound (HIFU), photodynamic therapy using newly developed light-sensitizing agents, and MRI-guided HIFU are all promising new tools.

KW - Focal therapy

KW - Male lumpectomy

KW - Prostate cancer

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=75149161565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149161565&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 5155

EP - 5161

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -